Activity and tolerability of nilotinib :
✍
Maya Koren-Michowitz; Philipp le Coutre; Justus Duyster; Christof Scheid; Panayi
📂
Article
📅
2010
🏛
John Wiley and Sons
🌐
English
⚖ 382 KB
## Abstract ## BACKGROUND: Nilotinib is active in imatinib‐resistant and ‐intolerant chronic myeloid leukemia patients and was recently approved for these indications. ## METHODS: Data on the efficacy and safety of nilotinib treatment were collected from 2 phase 2 expanded access clinical trials